The 23andMe Experience - A Lot of Knowledge is of Little Help?
By Alison Lashwood,
BioNews
| 02. 23. 2015
Untitled Document
The 23andMe test and other similar direct-to-consumer (DTC) genetic tests are likely here to stay. Those in favour see them as a way of engaging the public with science and making it fun, but there are problematic aspects, too. The issue of interpretation of the results is perhaps of greatest concern.
In BioNews 788, Professor Joyce Harper highlights some of the issues that the general public need to be aware of should they undertake such testing.
Read more...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...
By Rowan Walrath and Laurel Oldach, Chemical & Engineering News | 03.04.2026
Washington, DC—At a press conference held at the US Department of Health and Human Services headquarters on Feb. 23, two doctors from the University of Pennsylvania and Children’s Hospital of Philadelphia spoke about their hope for the future of...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
